Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03665922 Not yet recruiting - Prostate Cancer Clinical Trials

Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This study will test whether oral intake of a dietary supplement called BroccoMax®, which is a special blend of broccoli extract containing a chemical called sulforaphane (hereafter abbreviated as SFN), may result in changes in chemicals that feed prostate cancer. BroccoMax® is available over the counter.

NCT ID: NCT03664193 Not yet recruiting - Prostate Cancer Clinical Trials

MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer

SIBRT
Start date: September 30, 2018
Phase: N/A
Study type: Interventional

Prostate SBRT is a standard of care treatment for prostate cancer that has not spread to distant metastatic sites. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity. In this initial study, MRI guided treatment planning and delivery will be used to deliver 7 Gy to the entire prostate and seminal vesicles, with a selective boost of additional 0.5, 1.0, 1.5 or 2 Gy per fraction for total dose of 37.5, 40, 42.5 or 45 Gy to biopsy proven lesions, defined using MRI.

NCT ID: NCT03663218 Not yet recruiting - Prostate Cancer Clinical Trials

PreOperative RadioTherapy for High-Risk Prostate Cancer (PORT-PC Trial)

PORT-PC
Start date: September 20, 2018
Phase: N/A
Study type: Interventional

Men with prostate cancer with Gleason Score of 8 or greater or clinical/radiographic evidence of T3 disease will be considered for this trial.

NCT ID: NCT03660085 Not yet recruiting - Prostate Cancer Clinical Trials

Prostate Cancer Pre-Operative Empowerment Program

PC-PEP
Start date: November 3, 2018
Phase: N/A
Study type: Interventional

Each year over 20,000 men are diagnosed with prostate cancer in Canada with the majority undergoing some form of treatment option. Radical prostatectomy is a common procedure that is effective in the treatment of prostate cancer. However, it typically incurs both short- and long-term side effects (e.g. urinary incontinence, sexual dysfunction, reduced physical function, etc) that can negatively impact one's quality of life. This study aims to educate and teach pre- (as opposed to most common post-) habilitation - preventive life habits aimed to empower men and address many of the issues faced by men undergoing radical prostatectomy or other active forms of prostate cancer treatments. The investigators hypothesize that daily text and email reminders will improve participant adherence to the prehabilitation program. Secondary objectives will assess change in physical fitness, urological symptoms, state of relaxation, and quality of life parameters before and after the program.

NCT ID: NCT03650153 Not yet recruiting - Prostate Cancer Clinical Trials

Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This prospective study of comparing between Transrectal and transperineal prostate MRI targeted biopsy to provide evidence for clinicians to select the appropriate biopsy approach under different conditions.

NCT ID: NCT03644303 Not yet recruiting - Prostate Cancer Clinical Trials

Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

TRAP
Start date: September 1, 2018
Phase: N/A
Study type: Interventional

This multi-center, phase II trial will be conducted in men with castration resistant prostate cancer. The aim of the TRAP trial is to test whether a new precise radiotherapy technique called stereotactic body radiotherapy (SBRT) can slow down the growth of metastatic prostate cancer. If SBRT is effective it will represent a new treatment option in these patients, providing more prolonged control without having to resort to chemotherapy and its potentially unpleasant side effects. In this trial, the investigators will identify men who, despite being on next generation androgen deprivation treatment (Abiraterone or Enzalutamide) have developed one or two new sites of worsening (growing) disease but the rest of their cancer is still responding to hormonal therapy. If it is the case that SBRT can successfully treat the cancer which is resistant to current treatment then the investigators hope they will be able to better control the spread of cancer in these patients for longer. The investigators also hope that they will be able to use the tell-tale products (gene markers) that are released into the bloodstream in these patients, or identify characteristics on novel imaging such as magnetic resonance imaging (MRI) to help identify patients in the future who will benefit the most.

NCT ID: NCT03637543 Not yet recruiting - Prostate Cancer Clinical Trials

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

Start date: September 30, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab

NCT ID: NCT03635866 Not yet recruiting - Prostate Cancer Clinical Trials

PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy

Start date: September 14, 2018
Phase: N/A
Study type: Interventional

The principal aim of this study is to determine if PET/MRI imaging with 18-F fluciclovine (Axumin) identifies those men with false negative MRI fusion targeted biopsy (MRFTB) of PI-RADS 4 and 5 lesions. PI-RADS 4 and 5 MRI lesions are highly suspicious for clinically significant prostate cancer and require future repeat MRI imaging and possible repeat prostate biopsy depending on the results of the repeat MRI. Men, who had negative MRFTB within past 12 months of PI- RADS 4 or 5 MRI lesion will be included in this diagnostic study. The repeat MRI is standard of care at NYU Langone Health. The investigation aspect of the study is to perform an Axumin scan the same day as the MRI. Those men with persistent highly suspicious lesions will under MRFTB. The biopsy results will be compared with intensity of Axumin uptake within the prostate. The urologist will have the discretion to biopsy Axumin avid lesions not detected by MRI.

NCT ID: NCT03630926 Not yet recruiting - Prostate Cancer Clinical Trials

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

VPAC
Start date: August 2018
Phase:
Study type: Observational

This is a double-blind, study to evaluate the performance of NV-VPAC1 PCa Urine Diagnostic Test in three distinct populations being treated at the Intermountain Urology Clinic. The first population (positive control) is comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy. The second population (negative control) is comprised of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP). The third population (negative control) is comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.

NCT ID: NCT03630666 Not yet recruiting - Prostate Cancer Clinical Trials

Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients

OLIGOPELVIS2
Start date: November 2018
Phase: N/A
Study type: Interventional

Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is focused on delaying progression rather than eliminating all tumor burden. Local therapies, and specifically radiotherapy, have been directed at quality of life endpoints and not at improving survival. However, advances in imaging and systemic therapy have identified a population of 'oligometastatic' patients who have a lower burden of metastatic disease (usually ≤5 lesions), who may present an exception. This condition is hypothesized to occupy the hinterland between incurable metastatic disease and locoregional disease, where micrometastatic disease is assumed to exist and yet remain eradicable. Oligometastases can be detected using standard imaging but the sensitivity of these exams is very low for patients with a PSA below 10 ng/ml. In France, FCH PET imaging is now routinely available in a large majority of cancer centres. More recently, PSMA PET imaging has been developed. Since most oligometastases are now discovered at a time when conventional imaging is unable to detect metastases, we must rely on the literature regarding purely biochemically-relapsing prostate cancer patients. Three strategies have been explored: (i) observation until symptoms develop, (ii) early intermittent Androgen Deprivation Therapy (IADT) and (iii) continuous Androgen Deprivation Therapy (ADT). Recent data suggest that, of the three strategies, early intermittent ADT was superior in term of overall survival to observation in controlling metastatic prostate cancer, and this effect was similar in the biochemically-relapsing prostate cancer patient population. This phase III study will explore the role of salvage pelvic IG-IMRT combined with intermittent ADT (IADT) in pelvic oligometastatic patients in prolonging the first failure-free interval between the first and the second intermittent ADT courses.